Issue link: https://www.e-digitaleditions.com/i/1254974
Inhalation JUNE 2020 17 17. Lyons C, Callaghan M. e use of high- ow nasal oxygen in COVID-19. Anaesthesia 2020. 2020; https://doi.org/10.1111/anae.15073. 18. Bräunlich J, Wirtz H. Oral versus nasal high- ow bronchodilator inhalation in chronic obstructive pul- monary disease. Journal of Aerosol Medicine and Pul- monary Drug Delivery. 2018;31(4):248-254. 19. Bressan S, Balzani M, Krauss B, Pettenazzo A, Zan- conato S, Baraldi E. High- ow nasal cannula oxygen for bronchiolitis in a pediatric ward: A pilot study. Euro- pean Journal of Pediatrics. 2013;172(12):1649-1656. 20. Li J, Harnois LJ, Markos B, Roberts KM, Homoud SA, Liu J, et al. Epoprostenol delivered via high ow nasal cannula for ICU subjects with severe hypoxemia comorbid with pulmonary hypertension or right heart dysfunction. Pharmaceutics. 2019;11(6):281. 21. Milési C, Essouri S, Pouyau R, Liet J-M, Afa- netti M, Portefaix A, et al. High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory manage- ment of acute viral bronchiolitis in young infants: A multicenter randomized controlled trial (TRA- MONTANE study). Intensive Care Medicine. 2017;43(2):209-216. 22. Réminiac F, Vecellio L, Bodet-Contentin L, Gis- sot V, Le Pennec D, Gandonnière CS, et al. Nasal high-flow bronchodilator nebulization: A random- ized cross-over study. Annals of Intensive Care. 2018;8(1):128. 23. Réminiac F, Vecellio L, Heuzé-Vourc'h N, Petitcol- lin A, Respaud R, Cabrera M, et al. Aerosol therapy in adults receiving high ow nasal cannula oxygen ther- apy. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2016;29(2):134-141. 8. Vyas TK, Shahiwala A, Marathe S, Misra A. Intra- nasal drug delivery for brain targeting. Current Drug Delivery. 2005;2(2):165-175. 9. Le Guellec S, Le Pennec D, Gatier S, Leclerc L, Cabrera M, Pourchez J, et al. Validation of anatomical models to study aerosol deposition in human nasal cav- ities. Pharmaceutical Research. 2014;31(1):228-237. 10. Forbes B, Bommer R, Goole J, Hellfritzsch M, de Kruijf W, Lambert P, et al. A consensus research agenda for optimising nasal drug delivery. Expert Opinion on Drug Delivery. 2020 [Accepted for publication]. 11. Grmaš J, Stare K, Božič D, Injac R, Dreu R. Elu- cidation of formulation and delivery device-related effects on in vitro performance of nasal spray with implication to rational product speci cation identi - cation. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2017;30(4):230-246. 12. Quadir M, Zia H, Needham TE. Toxicological implications of nasal formulations. Drug Delivery. 1999;6(4):227-242. 13. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clinical Pharmacokinetics. 2003;42(13):1107-1128. 14. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applica- tions, trends and future perspectives. Advanced Drug Delivery Reviews. 2005;57(11):1640-1165. 15. US Food and Drug Administration. Guidance for Industry: Nasal Spray and Inhalation Solution, Sus- pension, and Spray Drug Products, Chemistry, Man- ufacturing, and Controls Documentation. Federal Register. 2002;2002:1-49. 16. Guideline on the pharmaceutical quality of inhala- tion and nasal products. London: European Medicines Agency. 2006. EEC | mEEC | BAC | NAC | ePRO | eNO | SPUTUM Contact Cliantha Research today for your program planning and clinical trial conduct at: Cynthia Day O'Brien Senior Director, Business Development +1-507-208-5012 cobrien@cliantha.com We are a full-service, global, clinical stage CRO We use innovative approaches to fast track product development We specialize in respiratory drug development We help Innovators & Generics bring inhaler products to market "Because it's never too early to talk about clinical development"